Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.07 USD
−60.37 M USD
0.00 USD
18.69 M
About Kyverna Therapeutics, Inc.
Sector
Industry
CEO
Warner Biddle
Website
Headquarters
Emeryville
FIGI
BBG00RCYMHR1
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of KYTX is 4.39 USD — it has increased by 7.02% in the past 24 hours. Watch Kyverna Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kyverna Therapeutics, Inc. stocks are traded under the ticker KYTX.
KYTX stock has fallen by −11.96% compared to the previous week, the month change is a −17.73% fall, over the last year Kyverna Therapeutics, Inc. has showed a −87.18% decrease.
We've gathered analysts' opinions on Kyverna Therapeutics, Inc. future price: according to them, KYTX price has a max estimate of 48.00 USD and a min estimate of 6.00 USD. Watch KYTX chart and read a more detailed Kyverna Therapeutics, Inc. stock forecast: see what analysts think of Kyverna Therapeutics, Inc. and suggest that you do with its stocks.
KYTX reached its all-time high on Feb 8, 2024 with the price of 35.06 USD, and its all-time low was 4.30 USD and was reached on Nov 15, 2024. View more price dynamics on KYTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KYTX stock is 12.76% volatile and has beta coefficient of 1.71. Track Kyverna Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kyverna Therapeutics, Inc. there?
Today Kyverna Therapeutics, Inc. has the market capitalization of 189.41 M, it has decreased by −8.28% over the last week.
Yes, you can track Kyverna Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Kyverna Therapeutics, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
KYTX earnings for the last quarter are −0.80 USD per share, whereas the estimation was −0.81 USD resulting in a 1.75% surprise. The estimated earnings for the next quarter are −0.84 USD per share. See more details about Kyverna Therapeutics, Inc. earnings.
Kyverna Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
KYTX net income for the last quarter is −34.49 M USD, while the quarter before that showed −28.80 M USD of net income which accounts for −19.75% change. Track more Kyverna Therapeutics, Inc. financial stats to get the full picture.
No, KYTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 96.00 employees. See our rating of the largest employees — is Kyverna Therapeutics, Inc. on this list?
Like other stocks, KYTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kyverna Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kyverna Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kyverna Therapeutics, Inc. stock shows the strong sell signal. See more of Kyverna Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.